Dementia Case Study
Abstract
Dementia describes a spectrum of progressive neurodegenerative disorders that impair memory, thinking, behaviours and the ability to perform activities of daily living. Alzheimer’s disease (AD) accounts for roughly two‑thirds of dementia cases[1]. Global estimates indicate that more than 55 million people were living with dementia in 2021 and over 10 million new cases occur annually[2]. The economic burden is enormous; in 2019 the global cost of dementia exceeded US$ 1.3 trillion[3]. This case study explores the pathophysiology and risk factors of dementia, outlines diagnostic assessment and evidence‑based management, and presents a fictional case to illustrate the complexities of care. Emphasis is placed on nursing management, interprofessional collaboration and palliative care considerations.
Introduction
Dementia is an umbrella term describing a decline in cognitive ability severe enough to interfere with daily life[4]. It is not a normal part of ageing but is strongly age‑associated; prevalence approximately doubles every 5 years after age 65[5]. Alzheimer’s disease, the most common form, is characterized by insidious onset and progressive impairment of memory, language, reasoning and executive function[1]. Vascular dementia, dementia with Lewy bodies, frontotemporal lobar degeneration and other etiologies contribute to the remaining cases[6].
According to the World Health Organization (WHO), dementia is the seventh leading cause of death worldwide and one of the major causes of disability and dependency among older people[7]. Over 60 % of individuals with dementia live in low‑ and middle‑income countries[2]. By 2030 the number of people living with dementia is expected to reach 78 million and by 2050 nearly 139 million[8]. The direct medical costs account for only about 20 % of total dementia costs; most expenses arise from informal and social care[9].
Although age and genetics are important determinants, approximately 40 % of dementia cases may be attributable to modifiable risk factors such as hypertension, diabetes, obesity, depression, smoking, physical inactivity and social isolation[10]. Recognizing and addressing these factors present opportunities for prevention and early intervention. Timely diagnosis is crucial to allow persons with dementia and their families to plan care, access support services and participate in decisions. Nurses play a pivotal role in assessment, management, caregiver support and coordination of palliative care. The following sections summarize the pathophysiology, risk factors, clinical manifestations, assessment, management and nursing considerations of dementia and then apply these concepts to a comprehensive case study.
Pathophysiology and Etiology
Neuropathological hallmarks
The neuropathological signature of AD includes extracellular amyloid‑β (Aβ) plaques and intracellular neurofibrillary tangles composed of hype phosphorylated tau protein[11]. Two major hypotheses explain these changes:
- Cholinergic hypothesis: Degeneration of cholinergic neurons in the basal forebrain and neocortex leads to reduced levels of acetylcholine. Anticholinergic drugs exacerbate cognitive impairment. Aβ accumulation is thought to cause cholinergic synaptic loss and impaired neurotransmitter release[12].
- Amyloid cascade hypothesis: Abnormal processing of amyloid precursor protein (APP) by β‑ and γ‑secretases generates Aβ peptides, particularly the neurotoxic Aβ42 fragment[13]. Aβ42 aggregates into fibrils, forming plaques that trigger neuroinflammation, oxidative stress and synaptic dysfunction[13].
Genetic factors contribute to pathogenesis. Mutations in the APP gene on chromosome 21, presenile 1 (PSEN1) on chromosome 14 and presenilin 2 (PSEN2) on chromosome 1 account for about 5–10 % of AD cases and are associated with early‑onset autosomal‑dominant disease[14]. The ε4 allele of apolipoprotein E (APOE) is the most important genetic risk factor for late‑onset AD; heterozygous carriers have a 3‑fold increased risk and homozygous carriers have a 15‑fold increased risk[15].
Other forms of dementia have distinct pathology. Vascular dementia results from ischemic or hemorrhagic cerebrovascular disease that causes stepwise cognitive decline[16]. Dementia with Lewy bodies is characterized by accumulation of α‑synuclein protein in cortical neurons and presents with fluctuating cognition, parkinsonism and visual hallucinations[17]. Frontotemporal dementia involves degeneration of the frontal and temporal lobes and manifests with personality changes, disinhibition and language difficulties[18]. Mixed pathology (e.g., AD with vascular contributions) is common[19].
Neuroinflammation and other mechanisms
Beyond plaques and tangles, neuroinflammation, oxidative stress and mitochondrial dysfunction play important roles. Microglial activation around Aβ plaques releases inflammatory mediators and reactive oxygen species that contribute to neuronal injury[20]. Dysregulation of metal homeostasis (iron, copper, zinc) and accumulation of toxic proteins such as TDP‑43 have also been implicated[21]. In Down syndrome (trisomy 21), an extra copy of APP leads to increased Aβ production; nearly all individuals with Down syndrome develop AD pathology by midlife[22].
Etiologic subtypes
The Diagnostic and Statistical Manual of Mental Disorders (DSM‑5) recognizes multiple etiological subtypes of major neurocognitive disorder: Alzheimer’s disease, vascular disease, frontotemporal lobar degeneration, Lewy body disease, Parkinson disease dementia, HIV infection, Huntington disease, prion disease, substance use, traumatic brain injury and others[23]. Multiple etiologies can coexist (e.g., mixed AD and vascular dementia), emphasizing the need for comprehensive evaluation.
Risk Factors and Epidemiology
Age is the strongest risk factor for dementia; prevalence doubles every five years after age 65[5]. Cardiovascular disease (CVD) is an important modifiable risk factor; it increases the risk of AD and vascular dementia[24]. Other modifiable factors include obesity and diabetes, which impair glucose tolerance and promote insulin resistance and chronic inflammation that accelerates Aβ accumulation[25]. Traumatic brain injury, depression, smoking, low educational attainment and hyperhomocysteinemia also contribute to risk[26]. Protective factors include higher education, estrogen use in women, anti‑inflammatory agents, cognitive leisure activities, a healthy diet and regular aerobic exercise[27].
The WHO lists additional modifiable risk factors: hypertension, high blood sugar, obesity, smoking, excessive alcohol consumption, physical inactivity, social isolation and depression[10]. A CDC analysis of adults aged ≥45 years identified eight modifiable risk factors hypertension, physical inactivity, obesity, diabetes, depression, current smoking, hearing loss and binge drinking and found that prevalence of subjective cognitive decline increased from 3.9 % among adults with no risk factors to 25 % among those with four or more[28]. Family history and genetic susceptibility, particularly the APOE ε4 allele, increase risk[15], while a first‑degree relative with AD raises the risk by 10–30 % and having two affected siblings triples the risk[26].
Global prevalence of dementia rose from 20.3 million in 1990 to 43.8 million in 2016[29]. Forecasts suggest that the number will reach 150 million by 2050[29]. Dementia currently affects over 55 million people worldwide[2], with more than 60 % living in low‑ and middle‑income countries[2]. Every 3.2 seconds someone develops dementia[30]. Women bear a disproportionate burden, experiencing higher disability‑adjusted life years and providing 70 % of informal care hours[31]. The global cost of dementia exceeded US$ 1.3 trillion in 2019 and is projected to rise to US$ 2.8 trillion by 2030[3][32].
Clinical Presentation and Staging
Dementia develops insidiously and progresses over years. Early symptoms include forgetting recent events, misplacing objects, getting lost in familiar environments, losing track of time and difficulty following conversations[33]. Personality and behavioral changes such as anxiety, agitation, apathy or inappropriate behaviours may precede cognitive symptoms[34]. As the disease advances, individuals may struggle with complex tasks, lose the ability to recognize loved ones, require assistance with activities of daily living and eventually become bedridden[35]. Neurologic symptoms vary by subtype Lewy body dementia presents with visual hallucinations, parkinsonism and REM sleep behaviours disorder[17]; frontotemporal dementia causes disinhibition and language impairment[18]; vascular dementia causes stepwise declines[16].
Staging systems
The Global Deterioration Scale (also called the Functional Assessment Staging – FAST) divides dementia into seven stages[36]:
- No cognitive decline: Normal function; occasional memory lapses not apparent to others.
- Very mild cognitive decline: Self‑perceived memory lapses but preserved function.
- Mild cognitive decline: Increased memory lapses and occasional difficulty with work and social functioning; family notices subtle deficits.
- Moderate cognitive decline: Clear difficulty in finances, planning and complex tasks; orientation problems; requires assistance with instrumental activities of daily living.
- Moderately severe decline: Needs help with choosing clothing; may forget addresses and recent events.
- Severe decline: Requires assistance with dressing, eating and toileting; personality changes; incontinence; agitation and wandering[37].
- Very severe decline: Loss of verbal ability and psychomotor skills; requires total assistance; median survival 1.3 years in stage 7[38].
Early‑onset AD (before 65 years) represents about 5 % of cases and often follows a more aggressive course[39]. Late‑onset AD (after 65 years) is far more prevalent. Symptoms may plateau temporarily but overall progression is inevitable.
Diagnosis and Assessment
History and physical examination
Comprehensive history from the patient and caregivers is essential. Patients may present with memory loss, mood changes, social withdrawal, aggression, difficulty performing tasks and other cognitive deficits[40]. History should include comorbid conditions, medications and substance use. Clinicians must evaluate safety concerns such as driving, wandering, ability to use the telephone and vulnerability to abuse[41]. Family members often recognize deficits earlier than patients[42].
A focused physical and neurological examination assesses gait, reflexes and focal deficits. Differential diagnosis should consider depression (“pseudo‑dementia”), delirium, vitamin deficiencies, thyroid disorders and other reversible causes. Ataxia, visual changes, myoclonus or parkinsonism may suggest Creutzfeldt‑Jakob disease, Lewy body dementia or other atypical etiologies[17].
Cognitive screening tools
Multiple tools are available to quantify cognitive impairment. The Mini‑Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are commonly used; the MoCA is more sensitive for mild cognitive impairment and takes about 10 minutes to administer[43]. The Mini‑Cog is a brief three‑minute screening tool; the Rowland Universal Dementia Assessment Scale (RUDAS) assists cross‑cultural assessment[44]. Scores provide a baseline and can monitor progression; they do not alone diagnose dementia because functional decline must also be present[45]. Nurses should perform periodic cognitive assessments and report changes[46].
Laboratory and imaging evaluation
Baseline laboratory tests include complete blood count, metabolic panel, vitamin B12, folic acid, thyroid function tests and syphilis and HIV serology[47]. Additional tests (erythrocyte sedimentation rate, heavy metal screen, Lyme disease titers, ceruloplasmin) may be indicated based on clinical suspicion[48]. Neuroimaging is important when the onset is early, progression is rapid, or diagnosis is uncertain. Magnetic resonance imaging (MRI) without contrast is typically the first study; computed tomography (CT) is used when MRI is contraindicated[49]. Positron emission tomography (PET) scans using amyloid or tau tracers assist in research and in selected clinical cases[50]. Cerebrospinal fluid analysis of Aβ and phospho‑tau provides additional biomarkers.
Diagnostic criteria and differential diagnosis
Unlock the full article for USD 1.90
For just $1.9, unlock this professionally written case study sample and support the researchers behind our academic resources. These small access fees help fund the research, writing, and academic review process behind every sample we publish.
Sign in with Google, then pay to unlock on any device.
Secure checkout. You will return here automatically after payment.
